Summary: On the Enhanced Therapy Podcast, Ingmar Gorman, Ph.D., a Principal Investigator of MAPS’ first Phase 3 trial of MDMA-assisted therapy for PTSD, analyzes the study’s results and considers its potential implications in the decades to come.
Originally appearing here.